Compare Adaptive Biotechnologies Corp (ADPT) vs Ferrari NV (RACE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Ferrari NV — how do they compare? Adaptive Biotechnologies Corp trades at $25.26 (market cap $4.02B), while Ferrari NV trades at $410.01 (market cap $71.34B). The key difference: Ferrari NV is far larger — about 17.7× Adaptive Biotechnologies Corp's market cap, and Ferrari NV pays a 1.04% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | RACE | |
|---|---|---|
Market Cap | $4.02B | $71.34B |
Sector | Health | Consumer Cyclical |
52-Week High | $25.45 | $504.09 |
52-Week Low | $12.30 | $314.63 |
Enterprise Value | $4.08B | $73.27B |
Dividend Yield | — | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adaptive Biotechnologies (ADPT) trades at $25.24, near its 52-week high, with a bullish technical outlook. The company is executing a strategic separation into a pure-play MRD diagnostics business, showing strong revenue growth of 49% year-over-year in MRD and improving margins. Despite persistent net losses, cash flow turned positive in 2025, and recent earnings have mostly beaten expectations, indicating operational progress.
The outlook is cautiously optimistic, driven by the business separation potentially unlocking value and the MRD segment's growth. Key risks include sustained profitability challenges and high valuation multiples. Analyst consensus is bullish with a $25.50 price target, but investors should weigh the growth potential against the company's current lack of earnings.
Ferrari (RACE) trades at $407.21, up 0.11% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported Q2 2026 EPS of $2.99, beating estimates of $2.83, and raised full-year guidance, driven by robust personalization demand and pricing power. Revenue growth has been consistent, with 2025 revenue at $7.15 billion and net income margin of 22.25%, though valuation multiples like P/E of 37.93 are elevated.
The outlook remains positive given earnings beats, raised guidance, and analyst consensus favoring buys, but risks include high valuation sensitivity and economic cyclicality. Upside to the $462.67 price target depends on sustained premium demand execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →
